CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs

July 04, 2025 01:25 PM AEST | By Team Kalkine Media

CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs — Image source: Shutterstock

CSL Ltd Maintains Fundamentals While Share Price Softens

CSL Ltd, a global biotechnology company known for its blood plasma therapies and vaccine innovations, has faced a prolonged decline in its share price performance. The stock has struggled to maintain momentum this year, falling out of favour with market participants even as operational results show continued expansion across revenue and profit lines.

While broader sentiment has rotated toward cyclical and financial stocks in recent months, CSL has stayed committed to advancing its product portfolio and investing in manufacturing capacity across key regions. Despite market hesitation, the company maintains its presence as a heavyweight in the healthcare sector on the ASX 100, supported by a resilient long-term strategy and global reach.

Endeavour Group's Retail Brands Anchor Market Position

Endeavour Group Ltd, the retail drinks and hospitality company known for its BWS and Dan Murphy’s store networks, has also traded below its initial post-listing valuation. Since being spun out of Woolworths, the company has faced a number of structural and leadership challenges. However, its extensive market footprint in alcohol retailing continues to serve as a stabilising factor.

Despite subdued price action, Endeavour’s scale, diversified outlets, and positioning within an essential services sector have preserved its standing on the ASX 100. With store formats catering to both value-focused and premium consumers, the company continues to navigate industry headwinds through brand strength and operational continuity.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.